An interleukin-6 promoter variant is not associated with an increased risk for Alzheimer's disease

Candan Depboylu, Frank Lohmüller, Petra Gocke, Yansheng Du, Reinhilde Zimmer, Thomas Gasser, Thomas Klockgether, Richard C. Dodel

Research output: Contribution to journalArticle

22 Scopus citations


Recent studies have implicated interleukin-6 (IL-6) in the pathogenesis of Alzheimer's disease (AD). Neuro-inflammatory processes surrounding the amyloid plaques contribute to the progression of AD-related neurodegeneration. IL-6 is a multifunctional inflammatory cytokine which possibly acts as a mediator in the local immune response in the brain of AD patients. In this study we investigated whether the risk of developing AD is altered in carriers of the C allele of a G/C polymorphism at position -174. 113 AD patients and 108 age- and gender-matched nondemented control subjects were analysed. Genotyping of IL-6 was performed using standard PCR and restriction fragment length polymorphism methods. The results were adjusted for age, gender and apolipoprotein E ε4 status. There was no evidence for an association between the polymorphism and the risk of developing AD. No evidence of an earlier age at onset for carriers of the C allele was evaluated. We conclude that IL-6 (-174) polymorphism does not influence the risk of developing AD in our cohort.

Original languageEnglish (US)
Pages (from-to)170-173
Number of pages4
JournalDementia and Geriatric Cognitive Disorders
Issue number3
StatePublished - Jan 1 2004



  • Cytokine
  • Neurodegeneration
  • Polymorphism
  • Pro-inflammatory cytokines

ASJC Scopus subject areas

  • Neuropsychology and Physiological Psychology
  • Geriatrics and Gerontology

Cite this

Depboylu, C., Lohmüller, F., Gocke, P., Du, Y., Zimmer, R., Gasser, T., Klockgether, T., & Dodel, R. C. (2004). An interleukin-6 promoter variant is not associated with an increased risk for Alzheimer's disease. Dementia and Geriatric Cognitive Disorders, 17(3), 170-173.